Details
Stereochemistry | ACHIRAL |
Molecular Formula | C13H16N2S2 |
Molecular Weight | 264.41 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C1CCC(CC1)NSC2=NC3=C(S2)C=CC=C3
InChI
InChIKey=DEQZTKGFXNUBJL-UHFFFAOYSA-N
InChI=1S/C13H16N2S2/c1-2-6-10(7-3-1)15-17-13-14-11-8-4-5-9-12(11)16-13/h4-5,8-10,15H,1-3,6-7H2
DescriptionCurator's Comment: Description was created based on several sources, including http://www.fda.gov/downloads/BiologicsBloodVaccines/Allergenics/UCM294327.pdf
Curator's Comment: Description was created based on several sources, including http://www.fda.gov/downloads/BiologicsBloodVaccines/Allergenics/UCM294327.pdf
N-cyclohexyl-2-benzothiazosulfenamide (Sulfenax® CBS) is used in rubber industry in processing of natural and synthetic rubber in rubber compounds as a fast accelerator of vulcanization with delayed action. N-cyclohexyl-2-benzothiazosulfenamide is a chemical allergen. It is used for diagnosis of contact allergy. It is a component of Mercapto Mix, used in the epicutaneous patch test, called T.R.U.E. TEST, approved by FDA in 1994. T.R.U.E. TEST is indicated for use as an aid in the diagnosis of allergic contact dermatitis in persons 18 years of age and older whose history suggests sensitivity to one or more of the 35 substances included on the T.R.U.E. TEST panels.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL6099 Sources: http://www.ncbi.nlm.nih.gov/pubmed/21590714 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | T.R.U.E. TEST Approved UseT.R.U.E. TEST is an epicutaneous patch test indicated for use as an aid in the diagnosis of allergic contact dermatitis in persons 18 years of age and older whose history suggests sensitivity to one or more of the 35 substances included on the T.R.U.E. TEST panels. Launch Date1993 |
Sample Use Guides
Apply the three adhesive panels of allergens and allergen mixes on healthy
skin of the back. Remove panels and evaluate the skin 48 hours after
application. Re-evaluate the skin 72 to 96 hours after application.
Route of Administration:
Topical
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/21590714
10 uM of N-cyclohexyl-2-benzothiazosulfenamide induced AhR-dependent gene expression in mouse hepatoma (H1L6.1c2) cells
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000185508
Created by
admin on Fri Dec 15 17:01:49 GMT 2023 , Edited by admin on Fri Dec 15 17:01:49 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB169427
Created by
admin on Fri Dec 15 17:01:49 GMT 2023 , Edited by admin on Fri Dec 15 17:01:49 GMT 2023
|
PRIMARY | |||
|
DTXSID5020360
Created by
admin on Fri Dec 15 17:01:49 GMT 2023 , Edited by admin on Fri Dec 15 17:01:49 GMT 2023
|
PRIMARY | |||
|
SUB61033
Created by
admin on Fri Dec 15 17:01:49 GMT 2023 , Edited by admin on Fri Dec 15 17:01:49 GMT 2023
|
PRIMARY | |||
|
2868
Created by
admin on Fri Dec 15 17:01:49 GMT 2023 , Edited by admin on Fri Dec 15 17:01:49 GMT 2023
|
PRIMARY | |||
|
100000134274
Created by
admin on Fri Dec 15 17:01:49 GMT 2023 , Edited by admin on Fri Dec 15 17:01:49 GMT 2023
|
PRIMARY | |||
|
202-411-2
Created by
admin on Fri Dec 15 17:01:49 GMT 2023 , Edited by admin on Fri Dec 15 17:01:49 GMT 2023
|
PRIMARY | |||
|
95-33-0
Created by
admin on Fri Dec 15 17:01:49 GMT 2023 , Edited by admin on Fri Dec 15 17:01:49 GMT 2023
|
PRIMARY | |||
|
7232
Created by
admin on Fri Dec 15 17:01:49 GMT 2023 , Edited by admin on Fri Dec 15 17:01:49 GMT 2023
|
PRIMARY | |||
|
C044169
Created by
admin on Fri Dec 15 17:01:49 GMT 2023 , Edited by admin on Fri Dec 15 17:01:49 GMT 2023
|
PRIMARY | |||
|
DB14200
Created by
admin on Fri Dec 15 17:01:49 GMT 2023 , Edited by admin on Fri Dec 15 17:01:49 GMT 2023
|
PRIMARY | |||
|
N0000175629
Created by
admin on Fri Dec 15 17:01:49 GMT 2023 , Edited by admin on Fri Dec 15 17:01:49 GMT 2023
|
PRIMARY | Increased Histamine Release [PE] | ||
|
N0000184306
Created by
admin on Fri Dec 15 17:01:49 GMT 2023 , Edited by admin on Fri Dec 15 17:01:49 GMT 2023
|
PRIMARY | Cell-mediated Immunity [PE] | ||
|
1306886
Created by
admin on Fri Dec 15 17:01:49 GMT 2023 , Edited by admin on Fri Dec 15 17:01:49 GMT 2023
|
PRIMARY | RxNorm | ||
|
UCA53G94EV
Created by
admin on Fri Dec 15 17:01:49 GMT 2023 , Edited by admin on Fri Dec 15 17:01:49 GMT 2023
|
PRIMARY | |||
|
UCA53G94EV
Created by
admin on Fri Dec 15 17:01:49 GMT 2023 , Edited by admin on Fri Dec 15 17:01:49 GMT 2023
|
PRIMARY | |||
|
N0000171131
Created by
admin on Fri Dec 15 17:01:49 GMT 2023 , Edited by admin on Fri Dec 15 17:01:49 GMT 2023
|
PRIMARY | Allergens [Chemical/Ingredient] | ||
|
4809
Created by
admin on Fri Dec 15 17:01:49 GMT 2023 , Edited by admin on Fri Dec 15 17:01:49 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD